CClinicalTrials.gg
Status unknownNCT05524675Updated Sep 1, 2022

The Effect of Multiple Medications on the Incidence of Organic Dyspepsia

An observational study in Dyspepsia, sponsored by Air Force Military Medical University, China. Status unknown at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-01.

Sponsored by Air Force Military Medical University, China · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Dyspepsia is a very common gastrointestinal disease, presented as predominant symptom of upper abdominal pain. Underlying causes for dyspepsia can classified as organic or functional dyspepsia. Some medications (eg. non-steroid anti-inflammatory drugs (NSAIDs)) were associated with higher frequent incidences of organic lesions. Multiple medications showed an increased trend with aging of the population and multimorbidity. Multiple medications were suggested to be strongly relate to adverse drug events (ADEs), adverse drug reactions (ADRs), drug-drug interactions, and drug-disease interactions, which had been reported to lead to higher incidences of some diseases, including fractures, cognitive impairment and malnutrition. However, it was unknown if multiple medications was associated with more incidences of organic dyspepsia.

02

Conditions studied

  • Dyspepsia

Browse trials for

03

In context

Dyspepsia

363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.

This study's planned enrollment of 500 is above the median of 192 across 56 observational studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Air Force Military Medical University, China is the lead sponsor of 172 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients aged ≥ 18 years old who met broad criteria of dyspepsia with upper endoscopy and abdominal ultrasonography within one year were eligible for our study.

Inclusion criteria

  1. aged ≥18 years old
  2. patients who met broad criteria of dyspepsia
  3. undergoing upper endoscopy and abdominal ultrasonography within one year.

Exclusion criteria

Exclusion Criteria:

  1. organ failure defined by Marshall standard
  2. severe psychiatric illnesses
  3. suspected or identified bowel obstruction
  4. known malignancy
  5. pregnancy or lactation
  6. unable to provide consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. the rate of patients diagnosed with organic upper gastrointestinal (GI) diseases.

    All included patients underwent upper GI endoscopy and abdominal ultrasound and H. Pylori test. Barrett's esophagus, esophageal candidiasis, esophageal cancer, gastric ulcer, gastric erosion, gastric cancer, duodenal ulcer, duodenal erosion, cholecystitis, pancreatitis and biliary stones were classified as organic upper GI diseases.

    Time frame: 1 day

Secondary outcomes

  1. Functional dyspepsia

    Functional dyspepsia was defined by Rome IV criteria, which was based on symptom and duration rather than scores. Patients diagnosed as Rome IV criteria met one or more of following criteria: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. the above symptoms and durations were included in the questionaire. Physiological parameter was not required for Rome IV criteria.

    Time frame: 6 months

  2. Number of participants with different subtypes of functional dyspepsia

    Functional dyspepsia was based on Rome IV criteria, which was based on symptom and duration rather than scores. Functional dyspepsia was classified into three subgroups:(1) Postprandial Distress Syndrome, Must include one or both of the following at least 3 days per week: 1. Bothersome postprandial fullness (ie, severe enough to impact on usual activities) 2. Bothersome early satiation (ie, severe enough to prevent finishing a regular-size meal) (2) Bothersome epigastric pain, Must include at least 1 of the following symptoms at least 1 day a week: 1. Bothersome epigastric pain (ie, severe enough to impact on usual activities) AND/OR 2. Bothersome epigastric burning (ie, severe enough to impact on usual activities). (3) mixed syndrome, defined when postprandial distress syndrome and epigastric pain syndrome presented simultaneously

    Time frame: 6 months

  3. Short Form of Nepean Dyspepsia Index (SF-NDI)

    The SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms ("stomach problems") on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study). Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.

    Time frame: 1 day

  4. Hospital anxiety scale

    Anxiety of patients are assessed by using Hospital Anxiety Scale.It contains 7 items, which assess symptoms experienced during the past week on a 0-3 scale. A subscore of \> 8 for anxiety would indicate a clinical case.

    Time frame: 1 day

  5. Hospital depression scale

    Depression of patients are assessed by using Hospital Depression Scale. It contains 7 items, which assess symptoms experienced during the past week on a 0-3 scale. A score of \> 8 for depression would indicate a clinical case.

    Time frame: 1 day

  6. Quality of Life scores

    Quality of Life scores assessed by Patient-reported outcomes measurement information system (PROMIS) Global-10 questionnaire.PROMIS Global-10 is a newly validated 10-question survey used to assess health care-related quality of life measures for the general population. It's a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient and a better quality of life.

    Time frame: 1 day

  7. Severity of functional dyspepsia judged by patients

    Patients rated the severity of functional dyspepsia as mild, moderate, and severe by themselves.

    Time frame: 1 day

  8. Number of participants with other functional gastrointestinal diseases

    Other functional gastrointestinal diseases#such as irritable bowel syndrome(IBS) or functional heartburn#etc.

    Time frame: 1 day

07

Study locations

1 of 4 sites recruiting
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
    • Xiaojun Huang, M.D. · Contact
    Not yet recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710032, China
    • Na Liu, M.D. · Contact
    Not yet recruiting
  • Xijing 986 Hospital
    Xi'an, Shaanxi 710032, China
    • Jun Wang, M.D. · Contact
    Not yet recruiting
  • Xijing Hospital of Digestive Diseases
    Xi'an, Shaanxi 710032, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05524675
Lead sponsor
Air Force Military Medical University, China
Responsible party
Yanglin Pan (professor, Air Force Military Medical University, China) — Principal investigator
First posted
Sep 1, 2022
Start date
Jun 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Sep 1, 2022

Study contacts

Yanglin Pan
Contact
yanglinpan@hotmail.com
13991811225

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion